

ASX Announcement

Pre-quotation disclosure

The following information is provided to ASX Limited (**ASX**) for release to the market in connection with the admission to the official list and official quotation of all of the fully paid ordinary shares (**Shares**) in BCAL Diagnostics Limited (ASX:BDX) (**Company**) in connection with the Company's initial public offering (**Offer**) of Shares pursuant to a prospectus lodged with the Australian Securities and Investments Commission on 4 June 2021 and with ASX on 11 June 2021 (**Prospectus**).

The Company confirms that the Offer closed on 2 July 2021 and the issue of 40,000,000 ordinary shares to investors at an issue price of \$0.25 per Share has been completed, with the Company raising \$10 million under the Offer. Allotment of the Shares available under the Offer completed on 15 July 2021.

In addition, 6,875,631 Shares were issued to PAC Partners Securities Pty Ltd (and its related parties) as lead manager to the Offer, in accordance with its mandate.

The Company applied for quotation of its Shares on, and admission to, the official list of ASX on 11 June 2021.

1. ASX Restricted securities

Number of securities	Restriction period
54,752,379 ordinary shares	24 months from the date of official quotation
9,246,318 ordinary options	24 months from the date of official quotation of the ordinary shares
20,596,692 ordinary shares	12 months from 20 February 2021 (being the date of issue of the shares)

2. Capital structure

The Company's capital structure is as set out below:

		undiluted %	diluted %
Shares			
Ordinary shares	206,875,633	100%	94.71%
Options			
Ordinary options Expiry: 30 January 2030 Exercise price: \$0.0574 each	2,311,560	-	1.06%
Ordinary options Expiry: 20 November 2029 Exercise price: \$0.0574 each	3,467,353	-	1.58%
Ordinary options Expiry: 23 November 2023 Exercise price: \$0.0574 each	5,778,965	-	2.65%
Total options	11,557,878	-	5.29%
<u>Total diluted share capital</u>	<u>218,433,511</u>	<u>100%</u>	<u>100%</u>

3. Waivers

The Company has received a waiver from the ASX of Listing Rule 1.1 condition 12 to the extent necessary to permit the Company to have on issue 11,557,878 options with an exercise price of less than \$0.20, on the condition that the material terms and conditions of the options are released as part of the Company's pre-quotation disclosure.

This announcement has been authorised by the board of directors of the Company.



Guy Robertson
Company Secretary